GSK shares fell after the U.K. drugmaker said it would stop working on an experimental treatment for chronic cough after ...

GSK plc GSK has announced that it is discontinuing development of camlipixant, an investigational P2X3 receptor antagonist, ...

Three years after buying Bellus Health and its chronic cough candidate camlipixant for around $2 billion, GSK is abandoning ...

Shares in GSK fell sharply on Friday after the pharma titan announced it was stopping the development of a refractory chronic ...

GSK (GSK) stock slips as the company discontinues a cough therapy added from its $2B Bellus Health acquisition following a ...

GSK plc provides an update on the CALM-1 and CALM-2 phase III clinical trials, which assessed the efficacy and safety of two doses of camlipixant (a P2X3 receptor antagonist) in adults with refractory ...

After GSK (GSK) announced it would discontinue a chronic cough therapy following a late-stage trial failure, Trevi ...

GSK has ended development of camlipixant in chronic cough after delivering mixed phase 3 data, dealing a major blow to a potential blockbuster that analysts saw as the key 2026 catalyst for the ...

GSK plc is halting work with camlipixant, a P2X3 receptor antagonist, in adults with refractory chronic cough (RCC) after reporting mixed results from the Calm-1 and Calm-2 phase III trials. The first ...

Nocion Therapeutics, Inc., a biopharmaceutical company developing novel small molecule therapies that selectively silence activated sensory neurons, today announced that it will be presenting a poster ...

Climate change, pollution, and longer allergy seasons are increasing persistent coughs, slowing recovery, and raising ...

More than two dozen fires continue to burn across Oregon, causing very unhealthy and even hazardous air quality in much of the state. And while forecasted storms may slow their progress, lighting from ...